Clinical-stage biotechnology company Biophytis SA (Euronext Growth Paris:ALBPS) (OTC:BPTSY) on Monday reported promising results from its Phase 2/3 COVA study of oral BIO101 (20-hydroxyecdysone) in the treatment of severe COVID-19 in hospitalised adults.
The findings were presented at the World Congress on Infectious Diseases in Paris, France.
Biophytis reported a statistically significant 43.8% reduction in the risk of early respiratory failure or death, along with a 44.6% reduction in the 90-day death rate. These positive findings come amid rising COVID-19 cases.
Acurx Pharmaceuticals presents positive Ibezapolstat Phase 2 clinical trial results for CDI
Technavio predicts increase in global peptide therapeutics market size
GSK secures global rights to CureVac's mRNA vaccines in new licensing deal
Biophytis reports positive Phase 2/3 results for COVID-19 treatment at WCID
SCG Cell Therapy's SCG142 IND application receives US FDA approval
EDX Medical to distribute cResponse cancer assay in UK and Nordics
Scancell Holdings announces evaluation agreement with major biotechnology company
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
YS Biopharma repays USD40m loan facility
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib